[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"complement-3-glomerulopathy-c3g\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:complement-3-glomerulopathy-c3g":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100633085",false,"NCT07522099","Chinese Adults With Kidney Disease","A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease","Inclusion Criteria:\n\n* Mean eGFR greater than or equal to 30 mL\u002Fmin\u002F1.73m2\n* Clinical evidence of active kidney disease\n* Treated with supportive care including an ACE inhibitor or ARB if applicable\n* Willing to receive required vaccinations\n* Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy\n\nExclusion Criteria:\n\n* Previous kidney transplant or major solid organ transplant\n* Required renal replacement therapy for more than 72 hours\n* Rapidly progressive glomerular nephritis or acute kidney injury\n* History of recurrent invasive infection\n* Current or previous use of C5 or CFB inhibitors (such as eculizumab, ravulizumab or iptacopan)\n* Active TB, HIV or other systemic infection\n* Abnormal liver function","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).",[25,26,27],"Immunoglobulin A Nephropathy (IgAN)","Complement 3 Glomerulopathy (C3G)","IC-MPGN",[29,30,27,31,32],"IgAN","C3G","complement mediated kidney diseases","IgA Nephropathy","RECRUITING","2026-06-23",{"date":36,"type":37},"2026-06-25","ACTUAL",{"date":39,"type":37},"2026-05-21",{"date":41,"type":19},"2029-01-21",{"name":43,"class":44},"ADARx Pharmaceuticals, Inc.","INDUSTRY",10,""]